Search:

Solulink Board of Directors

Walter Young — Chairman

Walt Young has more than 45 years’ experience in leading organizations. For the first 36 years, he held senior position at four public companies: BF Goodrich, The Budd Company, The Henley Group and Champion Enterprises. As Chair and CEO of Champion Enterprises (Fortune 500), Walt was recognized by Fortune as a "Superstar" and by the Harvard Business School as one of the 19 top business leaders of the 1990s. Since 2003, Walt has focused on entrepreneurial start-ups, including as a lead investor and Director for Accuri Cytometers (acquired by Becton, Dickinson in 2011). Walt has lead and assisted over 70 entities to raise more than $75M in capital. In addition to Solulink, Walt is currently on the board of seven other early stage companies, including Swift Biosciences and DeNovo Sciences. Since 2003, Walt has been a director at NRG Energy (NYSE:NRG). Walt is also an advisor for the Michigan Accelerator Fund.

Walt received a BA in History and Economics for Muskingum University, his MBA in Marketing and Management from Penn State University and an honorary doctorate in Public Service from Muskingum University.

Jack Ball — Chief Executive Officer

Jack Ball is President, Tyball Associates, LLC, a consulting company providing marketing strategies that are highly capital efficient to companies in the biotech tools space. In addition, he serves on the board of directors of five companies: 3D Biomatrix, IntelliCyt, RealBio Technology, Swift Bioscience and ViroCyt. Jack was recently the Chief Commercial Officer of Accuri Cytometers (acquired by Becton Dickinson in 2011). Prior to joining Accuri, Jack was CEO of Amnis Corporation, a venture backed technology start-up developing high-end imaging flow cytometers. He also served as Chief Commercial Officer for Molecular Probes, Inc. (now a part of Life Technologies), the world leader in reagents for molecular biology and cell analysis.

Prior to that, Jack was the Senior VP & General Manager of the Life Sciences Group at Orchid Biosciences. Jack was also a senior executive with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America.

John “Kip” Miller — Director

Mr. Miller is a co-founder and member of the Board of Directors at Tonbo Biosciences, and a member of the Board of Directors at Firefly BioWorks. He brings a solid track record of life science leadership with a strong background in commercial operations, and extensive experience in the life science research and diagnostic markets. Mr. Miller served as President of Genetic Systems at Life Technologies. From 2008 to 2011, he served as Senior Vice President of Biodiscovery at Invitrogen Corporation, which merged with Applied Biosystems in 2008 to form Life Technologies.

Prior to joining Invitrogen Corporation, Mr. Miller served in various capacities for BD including VP GM of BD Biosciences Research Cell Analysis Business, VP GM of BD Pharmingen and VP Sales and Service the America’s. Mr. Miller holds a B.S. in Packaging Engineering from Michigan State University.

Mark Horne— Director

Mark Horne is the chief executive officer and managing partner of Plymouth Ventures in Ann Arbor, MI. Plymouth is a regional, growth stage venture capital fund with core competencies in technology/software, advanced manufacturing and life sciences. Mark serves on the board of the Michigan Venture Capital Association, along with several Plymouth portfolio companies – Image Integration Systems, Lynx Network Group, Relume Technologies, XanEdu Publishing and FutureNet Security Solutions. Mark began his career with Price Waterhouse in Toronto and Philadelphia, and worked for 20 years as the chief financial officer of several privately-held growth stage businesses, ranging in size from $10 million to $150 million. Mark is a former NJ licensed CPA.

Mark holds an M.B.A. from Widener University and a B.B.A in business administration from Cedarville University.

Tim Mayleben — Director

Tim Mayleben is chief executive officer, president, and a member of the board of directors at Esperion Therapeutics. Previously he was president, CEO and a member of the board of directors at Aastrom Biosciences and an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. He has also been president, chief operating officer and a director of NightHawk Radiology Holdings, Inc. Mr. Mayleben also served as chief operating officer of the original Esperion Therapeutics, where he led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in February 2004 for $1.3 billion. Mr. Mayleben is on the advisory board of the Wolverine Venture Fund and serves as a director for several private life science companies.

Tim holds an M.B.A. with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.B.A. in business administration from the University of Michigan Ross Business School.

Solulink's Latest Headlines

6/2015 - Solulink and TriLink BioTechnologies Enter into Manufacturing and Distribution Agreement

1/24/14 - An article discussing Solulink’s new revolutionary dye mix and match antibody labeling technology, HybriLink™ was published in the January 24, 2014, ChemBioChem Journal. The article is the result of a collaboration between the University of Chicago and Solulink:
DNA-Directed Assembly of Antibody–Fluorophore Conjugates for Quantitative Multiparametric Flow Cytometry

Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer